Our identification of CHK1i as a strategy to enhance the anti-tumor activity of ERK inhibitor treatment contrasts with a previous study of non-PDAC cancers, in which ERK MAPK signaling was associated with CHK1i sensitivity and MEK inhibition drove CHK1i resistance (Lee et al., 2017). Here, MAP2K7 is linked to cancer.